Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2000 2
2001 3
2002 4
2003 2
2004 2
2005 4
2006 1
2007 2
2008 2
2009 1
2011 5
2012 1
2013 1
2014 2
2015 3
2016 2
2018 2
2019 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Gain of Chromosome 9q"
Page 1
Study of chromosome 9q gain, Notch pathway regulators and Tenascin-C in ependymomas.
Gupta RK, Sharma MC, Suri V, Kakkar A, Singh M, Sarkar C. Gupta RK, et al. J Neurooncol. 2014 Jan;116(2):267-74. doi: 10.1007/s11060-013-1287-z. Epub 2013 Nov 1. J Neurooncol. 2014. PMID: 24178439
The molecular changes leading to ependymal oncogenesis are not completely understood. We examined chromosome 9q33-34 locus for gain, potential oncogenes at this locus (Notch-1 and Tenascin-C) and Notch pathway target genes (Hes-1, Hey-2 & C-myc) in ependymomas b …
The molecular changes leading to ependymal oncogenesis are not completely understood. We examined chromosome 9q33-34 locus for gai …
Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
Fellay CN, Frappaz D, Sunyach MP, Franceschi E, Brandes AA, Stupp R. Fellay CN, et al. Curr Opin Neurol. 2011 Dec;24(6):626-32. doi: 10.1097/WCO.0b013e32834cd4b1. Curr Opin Neurol. 2011. PMID: 22027544 Review.
RECENT FINDINGS: The clinical risk stratification should be complemented with new molecular prognostic markers. Gene-expression profiling has permitted identification of four to six molecular medulloblastoma subgroups. ...Other subgroups are not so well defined and have ov …
RECENT FINDINGS: The clinical risk stratification should be complemented with new molecular prognostic markers. Gene-expression profi …
Molecular alterations associated with bladder cancer initiation and progression.
Cordon-Cardo C. Cordon-Cardo C. Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65. doi: 10.1080/03008880802291915. Scand J Urol Nephrol Suppl. 2008. PMID: 18815930 Review.
Deletions of chromosome 9, mainly allelic losses on the long arm (9q) are also frequent events in these tumors. ...Numerous individual molecular markers have been identified in the tissue specimens that correlate to some extent with tumor stage, and possibly with progno …
Deletions of chromosome 9, mainly allelic losses on the long arm (9q) are also frequent events in these tumors. ...Numerous individua …
Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas.
Miwa T, Hirose Y, Sasaki H, Ezaki T, Yoshida K, Kawase T. Miwa T, et al. Neurosurgery. 2011 Jan;68(1):206-12. doi: 10.1227/NEU.0b013e3181fd2c2e. Neurosurgery. 2011. PMID: 21099717
RESULTS: The most frequent CNA was single-copy gain of chromosome 1q, with 10 of 20 successfully investigated tumors showing the abnormality (50%). ...Gain of entire chromosome 7 was rare (2 cases), and codeletion of 1p and 19q was not detected. ...
RESULTS: The most frequent CNA was single-copy gain of chromosome 1q, with 10 of 20 successfully investigated tumors showing t …
PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. Field MG, et al. Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071. Clin Cancer Res. 2016. PMID: 26933176 Free PMC article.
Findings were validated using three independent datasets, including one using disomy 3 to identify low-risk UM. Chromosome copy number changes associated with Class1(PRAME+) tumors included gain of 1q, 6p, 8q, and 9q and loss of 6q and 11q. ...This finding may furth …
Findings were validated using three independent datasets, including one using disomy 3 to identify low-risk UM. Chromosome copy numbe …
Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A, Chocholous M, Gojo J, Dorfer C, Czech T, Heinzl H, Dieckmann K, Ambros IM, Ambros PF, Slavc I, Haberler C. Araki A, et al. Acta Neuropathol Commun. 2016 Aug 22;4(1):88. doi: 10.1186/s40478-016-0349-9. Acta Neuropathol Commun. 2016. PMID: 27550150 Free PMC article.
To date, the most promising candidate marker is chromosome 1q gain, which has been associated in independent studies with adverse outcome. ...We confirm the negative prognostic impact of 1q gain and TNC expression and could classify PF ependymomas by t …
To date, the most promising candidate marker is chromosome 1q gain, which has been associated in independent studies with adve …
Comparison of Clinical, Histopathological, and Genomic Features Between Malignant Peripheral Nerve Sheath Tumors and Cellular Schwannomas of the Eighth Cranial Nerve: A Case Series.
Zhao F, Zhang S, Du J, Chen Y, Wang B, Zhang J, He Q, Lin L, Zhang L, Yu Y, Liu P. Zhao F, et al. World Neurosurg. 2019 Feb;122:e487-e497. doi: 10.1016/j.wneu.2018.10.087. Epub 2018 Oct 23. World Neurosurg. 2019. PMID: 30366145
The common alterations in MPNSTs mainly included gains of chromosomes 7p, 8p, 9q, 12, and 17 and loss of heterozygosity of 1p, 6 and 9p. The common alterations in CSs included gain of 4p16.3, loss of heterozygosity of 2p15-14, and 22q11.1-13.3. ...
The common alterations in MPNSTs mainly included gains of chromosomes 7p, 8p, 9q, 12, and 17 and loss of heterozygosity of 1p, 6 and …
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Pfaff E, Witt H, Jones DT, Ryzhova M, Cho YJ, Wittmann A, Benner A, Weiss WA, von Deimling A, Scheurlen W, Kulozik AE, Clifford SC, Peter Collins V, Westermann F, Taylor MD, Lichter P, Pfister SM. Korshunov A, et al. Acta Neuropathol. 2012 Apr;123(4):515-27. doi: 10.1007/s00401-011-0918-8. Epub 2011 Dec 9. Acta Neuropathol. 2012. PMID: 22160402
Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role of MYCN oncogene amplification remains unresolved. We aimed to evaluate the prognostic value of this alteration alone and in combinat …
Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients. However, the prognostic role …
Clinical and cytogenetic characteristics of choroidal melanoma in Vietnamese Asians.
McCannel TA, Wu MY, Burgess BL. McCannel TA, et al. Mol Vis. 2011 Jan 21;17:231-6. Mol Vis. 2011. PMID: 21270969 Free PMC article.
Mapping Array and Expression Array revealed cytogenetic aberrations and gene expression profiles characteristic of choroidal melanoma. One patient (Case 2) with chromosome 3 loss and chromosome 8q gain developed biopsy-proven liver metastasis three years afte …
Mapping Array and Expression Array revealed cytogenetic aberrations and gene expression profiles characteristic of choroidal melanoma. One p …
Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B. Klein K, et al. J Clin Oncol. 2015 Dec 20;33(36):4247-58. doi: 10.1200/JCO.2015.61.1947. Epub 2015 Nov 16. J Clin Oncol. 2015. PMID: 26573082 Free PMC article.
Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than 150 mg/m(2) and etoposide doses greater than 500 mg/m(2) in the first induction course and high-dose cytarabine 3 g/m(2) during indu …
Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than …
39 results